{"id":407254,"date":"2021-01-04T07:03:28","date_gmt":"2021-01-04T12:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407254"},"modified":"2021-01-04T07:03:28","modified_gmt":"2021-01-04T12:03:28","slug":"autolus-therapeutics-to-participate-in-investor-conferences-through-january","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/","title":{"rendered":"Autolus Therapeutics to participate in Investor Conferences through January"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON, Jan.  04, 2021  (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>11 January 2021<\/strong> \u2013 The company will present at the <strong>H.C. Wainwright BioConnect 2021 Conference<\/strong> which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company\u2019s website at <a href=\"https:\/\/www.autolus.com\/investor-relations\/news-and-events\/events\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Autolus<\/a>.<\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>13 January 2021 <\/strong>\u2013 The company will present at the <strong>39th Annual J.P. Morgan Healthcare Conference<\/strong> on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company\u2019s website at <a href=\"https:\/\/www.autolus.com\/investor-relations\/news-and-events\/events\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Autolus<\/a>. <\/li>\n<\/ul>\n<p align=\"justify\">Archived replays will be available for a period of 30 days after the conferences.<\/p>\n<p align=\"justify\">\n        <strong>About Autolus Therapeutics plc<\/strong>\n      <\/p>\n<p align=\"justify\">Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.<\/p>\n<p align=\"justify\">\n        <strong>Contact: <\/strong>\n      <\/p>\n<p align=\"justify\">Lucinda Crabtree, PhD<br \/>Vice President, Investor Relations and Corporate Communications<br \/>+44 (0)\u00a07587 372 619\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KDBs-VaquotV7feQfV3zFderITUAAsMkygFql98vV4QaKuyT3KjyemqlKKxoX2NWcvV9leKfUo_eXgwTRKGC-VwkaJjjmnXje8_8CvIGlVI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">l.crabtree@autolus.com<\/a><\/p>\n<p align=\"justify\">Julia Wilson<br \/>+44 (0) 7818 430877<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2s4WqGki6xm_fIf9dXFZ369Op2wE7eZ6eBJ61PbTt71l4phgXdd3ARrFfnVdVpxFJMHHLCic04X0h0BJ4Jt6ub5EyZ_EGZ5lFA7b2T6r0t4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">j.wilson@autolus.com<\/a><\/p>\n<p align=\"justify\">Susan A. Noonan<br \/>S.A. Noonan Communications<br \/>+1-212-966-3650<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X_eB6wTI5Y7awv2w20A7_J6hhRmmcHD37YZaIcboKJisarKnPKhn8IrvMXf53hGJ-Z0sTkFMGyaGZ-LhvSLFsX93tiBRqqFh5aR9zooJMNQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">susan@sanoonan.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3a59702f-5fa2-444f-a35c-74cadb014df9\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021. 11 January 2021 \u2013 The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company\u2019s website at Autolus. 13 January 2021 \u2013 The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Autolus Therapeutics to participate in Investor Conferences through January&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407254","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autolus Therapeutics to participate in Investor Conferences through January - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics to participate in Investor Conferences through January - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021. 11 January 2021 \u2013 The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company\u2019s website at Autolus. 13 January 2021 \u2013 The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the &hellip; Continue reading &quot;Autolus Therapeutics to participate in Investor Conferences through January&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T12:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics to participate in Investor Conferences through January\",\"datePublished\":\"2021-01-04T12:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/\",\"name\":\"Autolus Therapeutics to participate in Investor Conferences through January - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=\",\"datePublished\":\"2021-01-04T12:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics to participate in Investor Conferences through January\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics to participate in Investor Conferences through January - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics to participate in Investor Conferences through January - Market Newsdesk","og_description":"LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) &#8212; Autolus Therapeutics plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021. 11 January 2021 \u2013 The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company\u2019s website at Autolus. 13 January 2021 \u2013 The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the &hellip; Continue reading \"Autolus Therapeutics to participate in Investor Conferences through January\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T12:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics to participate in Investor Conferences through January","datePublished":"2021-01-04T12:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/"},"wordCount":273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/","name":"Autolus Therapeutics to participate in Investor Conferences through January - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=","datePublished":"2021-01-04T12:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExOTYzMiMzOTAyMTE0IzIxMTA0Mjk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-participate-in-investor-conferences-through-january\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics to participate in Investor Conferences through January"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407254"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407254\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}